Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications that are effective treatment for patients with type 2 diabetes mellitus (T2DM) and weight control by stimulating insulin secretion, suppressing glucagon secretion, delaying gastric emptying and decreasing appetite. To investigate whether GLP-1RAs might have a positive impact in patients with knee OA, Zhu and colleagues analyzed data from a prospective, observational, multicenter study called the Shanghai Osteoarthritis Cohort
At our Doral clinic, the three use cases with the most clinical relevance are tendon and ligament recovery, gut-lining integrity, and systemic inflammation tied to a slow-healing injury
GLP-1 receptor agonists like semaglutide work partly by slowing gastric emptying and signaling satiety
Mutations in CPT1 can cause carnitine palmitoyltransferase I (CPT I) deficiency, which is an autosomal recessive genetic condition (need two copies of the mutation)
No more quick fixes or yo-yo dieting
194 In cell culture models, cathelicidin induced the expression of antiviral interferon response and significantly inhibited production of HSV-1
